PTNHealthcare · BiotechnologyThe 4 Wall Street analysts covering Palatin Technologies, Inc. hold a median 12-month price target of $50 — +695.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 13 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Palatin Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PTN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +695.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 12 Dec 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PTN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Palatin Technologies, Inc. returned −41.5% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 71% of US stocks
Cheaper than 49% of US stocks
Cheaper than 67% of US stocks
Higher than 99% of US stocks
Higher than 15% of US stocks
Higher than 8% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Palatin Technologies, Inc. has a market value of $11.7M and an enterprise value of $4.4M.
Revenue in the twelve months to 31 Mar 2026: $12.9M. The latest quarter grew 3278.8% year on year.
Net income over the same four quarters: −$6.2M, a −48.5% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$15.0M.
Trailing P/E: 91.2×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Palatin Technologies, Inc. employs 25 people — $515K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Palatin Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Palatin Technologies will report its first-quarter fiscal year 2027 operating results before U.S. financial markets open on November 17, 2026. The company will also hold a teleconference and webcast that day.
Why it matters — PTN watchers may note the scheduled results announcement and accompanying teleconference and webcast.
Palatin Technologies, Inc. (PTN) released the transcript of its Q4 2026 earnings call, covering the company's quarterly financial results and management commentary. The transcript was published on Seeking Alpha for investors and analysts.
Why it matters — A PTN watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's outlook.
Palatin reported fiscal year 2026 financial results, including $13.2 million in collaboration and license revenue and $7.5 million in cash as of June 30, 2026. The company also provided a business update outlining plans to initiate Phase 1 studies for once-weekly injectable and oral MC4R selective agonists in calendar 2027.
Why it matters — PTN watchers would care because the update details the timeline for its MC4R pathway programs targeting rare obesity disorders and signals that additional funding will be required to continue operations.
The article highlights roughly $2.9 billion and $10.0 billion of recent acquisitions in the rare-endocrine space and notes that IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, posted $71.3 million in global second-quarter 2026 revenue, up 19% sequentially. It states that Palatin Technologies is developing the next generation of this drug class.
Why it matters — A PTN watcher would care because the article frames market demand and commercial traction for MC4R agonists, the drug class Palatin is developing.
The 4 Wall Street analysts covering Palatin Technologies, Inc. have a median 12-month price target of $50, with estimates ranging from $12 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Palatin Technologies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palatin Technologies, Inc. 40 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Palatin Technologies, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +695.4% from the last close, and Ticker Nerd's factor model ranks Palatin Technologies, Inc. 40 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Palatin Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $60 over the next 12 months.
Palatin Technologies, Inc. returned -41.5% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system.
The most recent item we track (PRNewsWire, 13 Nov 2026): "Palatin to Report First Quarter Fiscal Year 2027 Results". Palatin Technologies will report its first-quarter fiscal year 2027 operating results before U.S. financial markets open on November 17, 2026. The company will also hold a teleconference and webcast that day.
Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system. Its current portfolio centers on receptor-targeted therapeutics for obesity, rare neuroendocrine disorders, inflammatory conditions, autoimmune diseases, and ocular disorders. The company’s work includes product candidates and partnered programs designed to address areas with significant unmet medical need, with a focus on selective peptide and small-molecule approaches. Palatin Technologies also participates in collaboration and licensing activities that support its research and development efforts across multiple therapeutic areas. Based in Princeton, New Jersey, Palatin Technologies Inc. operates as a clinical-stage company within the healthcare sector, where it contributes to the development of novel treatments aimed at specialized patient populations.
CEO Dr. Carl Spana Ph.D. · 25 employees · United States · https://palatin.com
